Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?

Bibliography

• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49(6):1374-403
   PubMed Web of Science ®Google Scholar
• Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v23-30
   PubMedGoogle Scholar
• Winter-Roach BA, Kitchener HC, Lawrie TA. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev 2012;3:CD004706
   Google Scholar
• Colombo N, Guthrie D, Chiari S, et al. International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003;95(2):125-32
   PubMed Web of Science ®Google Scholar
• Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst 2003;95(2):113-25
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17):3194-200
   PubMed Web of Science ®Google Scholar
• Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96(22):1682-91
   PubMed Web of Science ®Google Scholar
• Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991;9(10):1801-5
   PubMed Web of Science ®Google Scholar
• Elit L, Hirte H. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. Onco Targets Ther 2013;6:107-18
   PubMed Web of Science ®Google Scholar
• Vaage J, Donovan D, Mayhew E, et al. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993;72(12):3671-5
   PubMed Web of Science ®Google Scholar
• Raspollini MR, Castiglione F, Garbini F, et al. Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int J Surg Pathol 2005;13(2):135-42
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-83
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484-96
   PubMed Web of Science ®Google Scholar
• Pieretti M, Hopenhayn-Rich C, Khattar NH, et al. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 2002;20(1):11-23
   PubMed Web of Science ®Google Scholar
• Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000;89(9):2006-17
   PubMed Web of Science ®Google Scholar
• McCaughan H, Um I, Langdon SP, et al. HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis. J Clin Pathol 2012;65(7):670-1; author reply 71-2
   PubMed Web of Science ®Google Scholar
• Dian D, Lenhard M, Mayr D, et al. Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol 2013;28(2):239-44
   PubMed Web of Science ®Google Scholar
• Mawby WJ, Holmes CH, Anstee DJ, et al. Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem J 1994;304(Pt 2):525-30
   PubMedGoogle Scholar
• Corona G, Giannini F, Fabris M, et al. Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells. Int J Cancer 1998;75(1):125-33
   PubMed Web of Science ®Google Scholar
• Ponnusamy MP, Venkatraman G, Singh AP, et al. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett 2007;251(2):247-57
   PubMed Web of Science ®Google Scholar
• Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005;13(3):243-7
   PubMedGoogle Scholar
• Yakirevich E, Sabo E, Lavie O, et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 2003;9(17):6453-60
   PubMed Web of Science ®Google Scholar
• Toba S, Tenno M, Kurosaka A. An O-acetylated sialyl-Tn is involved in ovarian cancer-associated antigenicity. Biochem Biophys Res Commun 2000;271(2):281-6
   PubMed Web of Science ®Google Scholar
• Liu B, Nash J, Runowicz C, et al. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 2010;3:7
   PubMedGoogle Scholar
• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60
   PubMed Web of Science ®Google Scholar
• Piersma SJ, Jordanova ES, van Poelgeest MI, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007;67(1):354-61
   PubMed Web of Science ®Google Scholar
• O'Sullivan T, Saddawi-Konefka R, Vermi W, et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 2012;209(10):1869-82
   PubMed Web of Science ®Google Scholar
• Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117(5):1137-46
   PubMed Web of Science ®Google Scholar
• Bamias A, Koutsoukou V, Terpos E, et al. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol 2008;108(2):421-7
   PubMed Web of Science ®Google Scholar
• Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273
   PubMedGoogle Scholar
• Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419(6908):734-8
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61(12):4766-72
   PubMed Web of Science ®Google Scholar
• Raspollini MR, Castiglione F, Rossi Degl'innocenti D, et al. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 2005;16(4):590-6
   PubMed Web of Science ®Google Scholar
• Edwards RP, Gooding W, Lembersky BC, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 1997;15(11):3399-407
   PubMed Web of Science ®Google Scholar
• Vlad AM, Budiu RA, Lenzner DE, et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 2010;59(2):293-301
   PubMed Web of Science ®Google Scholar
• Schlienger K, Chu CS, Woo EY, et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003;9(4):1517-27
   PubMed Web of Science ®Google Scholar
• Goodell V, Salazar LG, Urban N, et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006;24(5):762-8
   PubMed Web of Science ®Google Scholar
• Hayashi K, Yonamine K, Masuko-Hongo K, et al. Clonal expansion of T cells that are specific for autologous ovarian tumor among tumor-infiltrating T cells in humans. Gynecol Oncol 1999;74(1):86-92
   PubMed Web of Science ®Google Scholar
• Halapi E, Yamamoto Y, Juhlin C, et al. Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas. Cancer Immunol Immunother 1993;36(3):191-7
   PubMed Web of Science ®Google Scholar
• Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181(6):2109-17
   PubMed Web of Science ®Google Scholar
• Kooi S, Freedman RS, Rodriguez-Villanueva J, Platsoucas CD. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res 1993;12(6):429-37
   PubMedGoogle Scholar
• Peoples GE, Anderson BW, Fisk B, et al. Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides. Ann Surg Oncol 1998;5(8):743-50
   PubMed Web of Science ®Google Scholar
• Dadmarz RD, Ordoubadi A, Mixon A, et al. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Cancer J Sci Am 1996;2(5):263-72
   PubMedGoogle Scholar
• Santin AD, Bellone S, Ravaggi A, et al. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol 2000;96(3):422-30
   PubMed Web of Science ®Google Scholar
• Peoples GE, Schoof DD, Andrews JV, et al. T-cell recognition of ovarian cancer. Surgery 1993;114(2):227-34
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348(3):203-13
   PubMed Web of Science ®Google Scholar
• Adams SF, Levine DA, Cadungog MG, et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009;115(13):2891-902
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102(51):18538-43
   PubMed Web of Science ®Google Scholar
• Leffers N, Gooden MJ, de Jong RA, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009;58(3):449-59
   PubMed Web of Science ®Google Scholar
• Milne K, Köbel M, Kalloger SE, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE 2009;4(7):e6412
   PubMed Web of Science ®Google Scholar
• Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114(6):1141-9
   PubMed Web of Science ®Google Scholar
• Garzetti GG, Cignitti M, Ciavattini A, et al. Natural killer cell activity and progression-free survival in ovarian cancer. Gynecol Obstet Invest 1993;35(2):118-20
   PubMed Web of Science ®Google Scholar
• Dong HP, Elstrand MB, Holth A, et al. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 2006;125(3):451-8
   PubMed Web of Science ®Google Scholar
• Knutson KL, Krco CJ, Erskine CL, et al. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol 2006;24(26):4254-61
   PubMed Web of Science ®Google Scholar
• Tchabo NE, Mhawech-Fauceglia P, Caballero OL, et al. Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. Cancer Immun 2009;9:6
   PubMedGoogle Scholar
• Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21(2):233-40
   PubMed Web of Science ®Google Scholar
• Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother 2007;56(3):271-85
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3(3):253-7
   PubMed Web of Science ®Google Scholar
• Meloni F, Morosini M, Solari N, et al. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006;67(1-2):1-12
   PubMed Web of Science ®Google Scholar
• Audia S, Nicolas A, Cathelin D, et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 2007;150(3):523-30
   PubMed Web of Science ®Google Scholar
• Li X, Ye DF, Xie X, et al. Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma. Cancer Invest 2005;23(5):399-403
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9
   PubMed Web of Science ®Google Scholar
• Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11(23):8326-31
   PubMed Web of Science ®Google Scholar
• Chen F, Hou M, Ye F, et al. Ovarian cancer cells induce peripheral mature dendritic cells to differentiate into macrophagelike cells in vitro. Int J Gynecol Cancer 2009;19(9):1487-93
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-49
   PubMed Web of Science ®Google Scholar
• Schmid MC, Varner JA. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol 2010;2010:201026
   PubMedGoogle Scholar
• Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010;59(10):1593-600
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104(9):3360-5
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8(3):190-8
   PubMed Web of Science ®Google Scholar
• Karim R, Jordanova ES, Piersma SJ, et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009;15(20):6341-7
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 2009;114(10):2149-58
   PubMed Web of Science ®Google Scholar
• Huarte E, Cubillos-Ruiz JR, Nesbeth YC, et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008;68(18):7684-91
   PubMed Web of Science ®Google Scholar
• Klink M, Jastrzembska K, Nowak M, et al. Ovarian cancer cells modulate human blood neutrophils response to activation in vitro. Scand J Immunol 2008;68(3):328-36
   PubMed Web of Science ®Google Scholar
• An X, Ding PR, Li YH, et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 2010;15(6):516-22
   PubMed Web of Science ®Google Scholar
• Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009;58(1):15-23
   PubMed Web of Science ®Google Scholar
• Ding PR, An X, Zhang RX, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 2010;25(12):1427-33
   PubMed Web of Science ®Google Scholar
• Kim HS, Han KH, Chung HH, et al. Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: a case-matched comparison. Eur J Surg Oncol 2010;36(7):691-8
   PubMed Web of Science ®Google Scholar
• Shimada H, Takiguchi N, Kainuma O, et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010;13(3):170-6
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Powell DJ, Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med 2012;10:157
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Powell DJ, Chiang CL, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013;2(1):e22664
   PubMed Web of Science ®Google Scholar
• Recchia F, Di Orio F, Candeloro G, et al. Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study. Gynecol Oncol 2010;116(2):202-7
   PubMed Web of Science ®Google Scholar
• Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011;13(1):98-107
   PubMed Web of Science ®Google Scholar
• Dobrzanski MJ, Rewers-Felkins KA, Samad KA, et al. Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate “Natural” and “Inducible” CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunol Immunother 2012;61(6):839-54
   PubMed Web of Science ®Google Scholar
• Wright SE, Rewers-Felkins KA, Quinlin IS, et al. Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother 2012;35(2):196-204
   PubMed Web of Science ®Google Scholar
• Burges A, Wimberger P, Kümper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13(13):3899-905
   PubMed Web of Science ®Google Scholar
• Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127(9):2209-21
   PubMed Web of Science ®Google Scholar
• Lindenmann J. Speculations on idiotypes and homobodies. Ann Immunol (Paris) 1973;124(2):171-84
   PubMedGoogle Scholar
• Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974;125C(1-2):373-89
   PubMedGoogle Scholar
• Reinartz S, Köhler S, Schlebusch H, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004;10(5):1580-7
   PubMed Web of Science ®Google Scholar
• Grisham RN, Berek J, Pfisterer J, Sabbatini P. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy 2011;3(2):153-62
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Harter P, Scambia G, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO–the MIMOSA study. J Clin Oncol 2013;31(12):1554-61
   PubMed Web of Science ®Google Scholar
• Berek J, Taylor P, McGuire W, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009;27(3):418-25
   PubMed Web of Science ®Google Scholar
• Berek JS, Taylor PT, Nicodemus CF. CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother 31(2):207-14
   PubMed Web of Science ®Google Scholar
• Ehlen TG, Hoskins PJ, Miller D, et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 2005;15(6):1023-34
   PubMed Web of Science ®Google Scholar
• Braly P, Nicodemus CF, Chu C, et al. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 2009;32(1):54-65
   PubMed Web of Science ®Google Scholar
• Yuan W, Xia G, Zhao C, et al. Anti-idiotypic single chain mimicking CA125 linked with tuftsin provides protective immunity against ovarian cancer in mice. Mol Med Rep 2012;5(2):388-94
   PubMed Web of Science ®Google Scholar
• Magee CN, Boenisch O, Najafian N. The role of costimulatory molecules in directing the functional differentiation of alloreactive T helper cells. Am J Transplant 2012;12(10):2588-600
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100(8):4712-17
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and. CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73(12):3591-603
   PubMed Web of Science ®Google Scholar